Nick Curzen
Prof Nick Curzen, University Hospital Southampton NHS Trust, and President of the British Cardiovascular Intervention Society, UK
ESC 2021: Late-breaking Science Video Collection
Published: 02 September 2021
-
Views:
2254
-
Likes:
7
Overview
Full programme
RIPCORD 2: FFR During Angiography Did Not Improve Patient Outcomes
- ENVISAGE-TAVI AF: Edoxaban noninferior to warfarin for adverse events after TAVI
- SYNTAX II Trial: 5yr Data Shows Reduction in MACE in PCI
- TWILIGHT-HBR: Ticagrelor Monotherapy in HBR Patients Undergoing PCI
- The LAAOS III Study: Surgical AFIB Ablation Evaluation
- TWILIGHT-Stent: Ticagrelor Monotherapy According to Stent Type
- STOPDAPT-2 ACT: 1-Month DAPT Followed by Clopidogrel Monotherapy in ACS
- SPLENDOR: Metabolic Surgery and Risk of MACE in NASH
- RESPONSE-2: Benefits of Community-based Lifestyle Programme Were Lost After 1yr in CAD Patients
- VOYAGER PAD: Rivaroxaban in Symptomatic PAD With & Without Comorbid Diabetes
- Micra CED: 2-Year Outcomes with Leadless Pacing
- RIPCORD 2: FFR During Angiography Did Not Improve Patient Outcomes
Overview
Our regular review series View from the Thoraxcenter hosted by Prof Nicolas Van Mieghem and Dr Joost Daemen (Thoraxcentre, Erasmus MC, Rotterdam, NL) provide a concise analysis of the late-breaking science results and spotlight impactful data.
For a deeper dive into key clinical trial data, Dr Harriette Van Spall (McMaster University, Hamilton, CA) interviewed principal investigators on their studies, learnings, and applicability to clinical practice in her regular Late-Breaker Discussion Series.
Short, accessible Expert Interviews were conducted with select faculty focusing on the results, applicability, and impact on future research.
More from this programme
-
View from the Thoraxcenter – What's Hot at ESC 2021
-
View from the Thoraxcenter: ESC 21 Late-breaking Science Wrap Up
-
ESC 2021 Discussion: The EMPEROR-Preserved Trial
-
ESC 2021 Discussion: The FIGARO-DKD Trial
-
ESC 2021 Discussion: The EMPEROR-Pooled Study
-
ENVISAGE-TAVI AF: Edoxaban noninferior to warfarin for adverse events after TAVI
-
SYNTAX II Trial: 5yr Data Shows Reduction in MACE in PCI
-
TWILIGHT-HBR: Ticagrelor Monotherapy in HBR Patients Undergoing PCI
-
The LAAOS III Study: Surgical AFIB Ablation Evaluation
-
TWILIGHT-Stent: Ticagrelor Monotherapy According to Stent Type
-
STOPDAPT-2 ACT: 1-Month DAPT Followed by Clopidogrel Monotherapy in ACS
-
SPLENDOR: Metabolic Surgery and Risk of MACE in NASH
-
RESPONSE-2: Benefits of Community-based Lifestyle Programme Were Lost After 1yr in CAD Patients
-
VOYAGER PAD: Rivaroxaban in Symptomatic PAD With & Without Comorbid Diabetes
-
Micra CED: 2-Year Outcomes with Leadless Pacing
-
RIPCORD 2: FFR During Angiography Did Not Improve Patient Outcomes
Faculty biographies
